• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Latest
  • Videos
  • Series
  • E-Newsletters
    • Fat Tail Daily
    • James Cooper’s Mining Memo
    • The Daily Reckoning Australia
  • Categories
    • Commodities
    • Macro
    • Market Analysis
    • Small Caps
    • Technology
  • Investment Guides
  • Premium Services
  • Editors
  • About
  • Contact Us
Fat Tail Daily
Subscribe
  • Home
  • Latest
  • Videos
  • E-Newsletters
  • Premium Services
Latest ASX News

PolyNovo Surges 15% On Record Q1 FY23 Sales

Like 0

By Kiryll Prakapenka, Thursday, 06 October 2022

Medical devices developer PolyNovo [ASX:PNV] increased more than 15% on Thursday following a strong Q1 FY23 sales updat

PolyNovo reported its ‘first ever A$5 million sales month and record first quarter sales.’

PNV shares have been up 55% over the past six months.

ASX:PNV polynovo chart

Source: tradingview.com

PolyNovo’s favourable first quarter

PNV’s September quarter sales rose 73% at the same time last year to $12.5 million, including a record month in September when sales totalled $5.4 million.

That $5.4 million from September means the other two months in the quarter averaged about $3.55 million per month.

Despite the record sales, PNV chairman David Williams admitted that month-to-month sales ‘are still lumpy.’

In FY22, PolyNovo’s total revenue increased 42.8% to $41.9 million, and net loss after tax fell 74% to $1.2 million.

The graph below depicts PolyNovo’s $1 million incremental sales milestones since April 2019:

ASX:PNV polynovo sales figues 2022

Source: PNV

Swami Raote, PNV’s CEO, commented on the quarterly results with the following statement:

‘Our results are a vindication of surgeon recognition of consistent outcomes, better patient experience along with hospital systems acknowledgement of lower complexity and cost associated with NovoSorb BTM. I am pleased with how our teams are now beginning to translate our burn heritage and supremacy into trauma and other acute surgical soft tissue reconstruction opportunities. PolyNovo has always been focused, responsible and capital efficient in delivering results and I look forward to accelerating our global impact.’

Chairman, David Williams added:

‘By focusing on hiring the right talent and expanding our commercial footprint, we are confident of building a Global leader in Soft Tissue Regeneration based in Australia. However, while the growth trajectory is clear and exciting, month to month sales are still lumpy.’

Hyper-bitcoinisation and the march to US$1 million

Do you think bitcoin can be worth US$1 million by 2030?

It might sound ludicrous, especially as Bitcoin is currently hovering around US$20,000 and is down 60% over the past 12 months.

But our crypto expert and Money Morning editor Ryan Dinse thinks the claim isn’t as farfetched as it might initially seem.

He’s actually preparing for the next crypto bull market right now.

He discussed how in a special presentation, which also sketched out his argument for how bitcoin can hit US$1 million by 2030.

If you’d like to hear Ryan’s thoughts, watch his presentation here.

Regards,

Kiryll Prakapenka,

For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The rare earths price disconnect
    By Dr. Lachlann Tierney

    The RBA could hike rates half an hour before the Melbourne Cup jumps. Meanwhile, a key rare earth price is up 23% this year while the stocks keep drifting. Why?

  • Commodities: Why You Need an International Focus
    By James Cooper

    Jurisdictional risk has many faces. The latest moves by the Australian Federal Government prove that no region is risk-free in the commodities market.

  • Welcome to peak chaos
    By Dr. Lachlann Tierney

    Bonds and copper are sending contradictory signals. When the noise gets this loud, fear does the pricing. Here’s why I’m testing the water in small-cap resources.

Primary Sidebar

Latest Articles

  • The rare earths price disconnect
  • Commodities: Why You Need an International Focus
  • Welcome to peak chaos
  • Did the Firmus IPO kill ASX small caps?
  • Higher For Longer Oil? Futures Say No!

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / AFSL: 323 988